Search Results 101-110 of 17294 for egfr

  1. Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease - Mayo Clinic

    At present, we are enrolling participants with CKD, with a subset of participants with diabetic kidney disease (DKD), aged 40-80 years, and eGFR 15-60 mL/min/ ...

  2. FORTIFI-HN01: A Study Of Ficerafusp Alfa (BCA101) Or Placebo In Combination With Pembrolizumab In First-Line PD-L1-pos, R Or M HNSCC - Mayo Clinic

    Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to ...

  3. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  4. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  5. Pulmonary Medicine Clinical Trials - Medical Professionals

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  6. A Study of Erlotinib as a Prevention in Trisomy 7 Positive Primary Sclerosing Cholangitis - Mayo Clinic

    Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist ...

  7. Pulmonary Medicine Clinical Trials - Medical Professionals

    ... EGFR mutant population. Patients will be enrolled over a three year period across approximately 25 geographically diverse academic as well as community ...

  8. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  9. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  10. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    eGFR >=30 mL/min/1.73m^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant: has been clinically ...